By Dominic Chopping

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders.

The Danish pharmaceutical giant said the drug was more effective than a daily growth hormone in children with Noonan syndrome--a genetic condition that stops typical development in some parts of the body--as well as compared to lower doses of a daily growth hormone in children born small for gestational age. Sogroya also worked at least as well in children with idiopathic short stature.

The company said children suffering from the conditions often face significant health challenges and a high treatment burden from daily injections.

"Children with growth failure face many health challenges beyond just being shorter than their peers," said Agnes Linglart, professor of pediatrics at the Bicetre Paris-Saclay University and Hospital in France and one of the lead investigators on the study.

"They often have metabolic disruptions and developmental difficulties that can seriously affect their wellbeing and quality of life, as well as long-term effects such as increased risk of cardiovascular disease or type 2 diabetes," she said.

Sogroya was well-tolerated, with no safety or tolerability issues identified compared to a once-daily growth hormone, Novo Nordisk said.

Results from a sub-study into Turner syndrome--a chromosomal disorder in females--will be available later this year.

The company has submitted Sogroya for regulatory review in both the European Union and the U.S. for the Noonan syndrome, children born small for gestational age and idiopathic short stature indications.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

May 12, 2025 03:03 ET (07:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.